About: Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Creator	Raoult, Didier Colson, Philippe Rolain, Jean-Marc Gautret, Philippe Brouqui, Philippe Parola, Philippe Lagier, Jean-Christophe Fenollar, Florence Fournier, Pierre-Edouard Million, Matthieu Drancourt, Michel Stein, Andreas Giraud-Gatineau, Audrey Tissot-Dupont, Hervé Scola, Bernard Chabrière, Eric Honoré, Stéphane Deharo, Jean-Claude Jacquier, Alexis Obadia, Yolande Hervé, Tissot-Dupont Scola, La Sté, Honoré Cortaredona, Sébastien Colson, Gautret Deharo, Stein Fournier, P-E Gaubert, J-Y Gaubert, Jean-Yves Million, Rolain, Fenollar Sé, Cortaredona
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: In our institute in Marseille, France, we initiated early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment with hydroxychloroquine and azithromycin (HCQ-AZ) was proposed for the positive cases. METHODS: We retrospectively report the clinical management of 3,737 screened patients, including 3,119 (83.5%) treated with HCQ-AZ (200 mg of oral HCQ, three times daily for ten days and 500 mg of oral AZ on day 1 followed by 250 mg daily for the next four days, respectively) for at least three days and 618 (16.5%) patients treated with other regimen (“others”). Outcomes were death, transfer to the intensive care unit (ICU), ≥10 days of hospitalization and viral shedding. RESULTS: The patients’ mean age was 45 (sd 17) years, 45% were male, and the case fatality rate was 0.9%. We performed 2,065 low-dose computed tomography (CT) scans highlighting lung lesions in 592 of the 991 (59.7%) patients with minimal clinical symptoms (NEWS score = 0). A discrepancy between spontaneous dyspnoea, hypoxemia and lung lesions was observed. Clinical factors (age, comorbidities, NEWS-2 score), biological factors (lymphocytopenia; eosinopenia; decrease in blood zinc; and increase in D-dimers, lactate dehydrogenase, creatinine phosphokinase, and C-reactive protein) and moderate and severe lesions detected in low-dose CT scans were associated with poor clinical outcome. Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days (odds ratios 95% CI 0.38 0.27–0.54) and shorter duration of viral shedding (time to negative PCR: HR 1.29 1.17–1.42). QTc prolongation (>60 ms) was observed in 25 patients (0.67%) leading to the cessation of treatment in 12 cases including 3 cases with QTc> 500 ms. No cases of torsade de pointe or sudden death were observed. CONCLUSION: Although this is a retrospective analysis, results suggest that early diagnosis, early isolation and early treatment of COVID-19 patients, with at least 3 days of HCQ-AZ lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.
has issue date	2020-06-25(xsd:dateTime)
bibo:doi	10.1016/j.tmaid.2020.101791
bibo:pmid	32593867
has license	no-cc
sha1sum (hex)	9999efa129aab13c71c3f287743df85238d8e29b
schema:url	https://doi.org/10.1016/j.tmaid.2020.101791
resource representing a document's title	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
has PubMed Central identifier	PMC7315163
has PubMed identifier	32593867
schema:publication	Travel Med Infect Dis
resource representing a document's body	covid:9999efa129aab13c71c3f287743df85238d8e29b#body_text
is schema:about of	named entity 'CORONAVIRUS DISEASE 2019' named entity 'EARLY TREATMENT' named entity 'PROPOSED' named entity 'OUR' named entity 'Marseille' named entity 'COVID-19' named entity 'France' named entity 'azithromycin' named entity 'Marseille' named entity 'coronavirus disease 2019' named entity 'lymphocytopenia' named entity 'hypertension' named entity 'proportional hazard model' named entity 'France' named entity 'mortality rate' named entity 'follow-up' named entity 'electrolytes' named entity 'zinc' named entity 'medical procedures' named entity 'Chinese province' named entity 'ageusia' named entity 'HCQ' named entity 'Marseille' named entity 'randomized clinical trials' named entity 'hydroxychloroquine' named entity 'nasopharyngeal' named entity 'Immunoglobulin' named entity 'anosmia' named entity 'oseltamivir' named entity 'Cough' named entity 'dyspnoea' named entity 'antiviral activity' named entity 'HCQ' named entity 'clinical outcome' named entity 'comorbidities' named entity 'ICU' named entity 'LDCT' named entity 'chronic respiratory disease' named entity 'IgA' named entity 'eosinopenia' named entity 'antiviral' named entity 'assay' named entity 'meta-analysis' named entity 'Marseille' named entity 'Viral load' named entity 'antibody titres' named entity 'clinical studies' named entity 'IgG' named entity 'LDCT' named entity 'Kaplan-Meier'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software